Hemab Therapeutics recently announced that the first patient has been dosed in their phase 1/2 clinical trial of HMB-002, an investigational subcutaneous therapy for patients with von Willebrand disease (VWD). It is developed with a monovalent antibody to increase levels of both von Willebrand factor and factor VIII. HMB-002 is a prophylactic therapy to prevent bleeding in people will all types of VWD.
The trial, known as Velora Pioneer, is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 in individuals with VWD
According to a Hemab press release, this first patient was administered HMB-002 at Richmond Pharmacology in London under the supervision of Principal Investigator, Dr. Ulrike Lorch. The study is currently enrolling additional participants. The company also presented preclinical data on HMB-002 at the recent 18thAnnual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).
“Von Willebrand Disease is characterized by a deficiency in VWF activity and sometimes associated with lowered levels of FVIII – both essential to control severe bleeding,” said Dr. Priyanka Raheja, the Royal London Hospital, Barts Health NHS Trust. “HMB-002 functions by increasing VWF and FVIII and could offer a complete disease correction for some and substantial modification for bleeding tendency for others. I am excited to be a contributing investigator on the Phase 1/2 trial.”
Source: Hemab Therapeutics press release dated February 27, 2025
